Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) continues to ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

ByInvesting.com • 08 Sept 2024 Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial ...

In extensive-stage small cell lung cancer, a trial evaluating ifinatamab deruxtecan led to a dose-response benefit in response rate, from 8 mg/kg up to 12 mg/kg, for a 26% overall response rate (per ...

00:10 | From the World Congress on Lung Cancer, some exciting data were recently presented by Charles Rudin regarding an antibody drug conjugate [ADC], I believe is pronounced ifinatamab deruxtecan [I ...

The ADC oncology market is experiencing rapid growth, attracting over 200 pharmaceutical companies vying for leadership in this innovative therapeutic space. As competition intensifies ...

(MENAFN- PR Newswire) The ADC oncology market is experiencing rapid growth, attracting over 200 Pharmaceutical companies vying for leadership in this innovative therapeutic space. As competition ...